Advertisement

Metformin May Lower Cardiac Dysfunction Risk During VEGF Inhibitor Therapy

Published on: 

Fadi Haroun, MD, discusses a retrospective analysis linking metformin to lower cardiac dysfunction risk in patients receiving VEGF inhibitors.

Vascular endothelial growth factor inhibitors (VEGFi) are essential antineoplastic agents, but cardiovascular toxicities, including heart failure, often limit their use. Metformin has pleiotropic effects which may protect the cardiovascular system independent of glucose lowering. A new retrospective analysis suggests metformin use at the start of VEGFi therapy is associated with a lower risk of cancer therapy-related cardiac dysfunction (CTRCD).¹

Fadi Haroun, MD, of The Ohio State University, presented the findings at the American Heart Association (AHA) Scientific Sessions 2026 and discussed them in an interview with HCPLive. Haroun called the results hypothesis generating rather than practice changing. He said prospective trials are needed to evaluate metformin as a cardioprotective agent.

What Did the Analysis Find About Metformin and CTRCD?

Haroun and colleagues used the TriNetX research network to identify adults with cancer who started VEGFi therapy between 2010 and 2024.¹ None of the patients had prior heart failure, cardiomyopathy, or a left ventricular ejection fraction (LVEF) below 50%. After propensity score matching for demographics, comorbidities, and baseline cardiovascular medications, the study included two cohorts of 15,769 patients each.¹

CTRCD was defined as a composite of new heart failure, cardiomyopathy, newly documented LVEF of 40% or lower, or the start of loop diuretic therapy.¹ Over up to one year of follow-up, metformin use was associated with a lower risk of CTRCD (17.2% vs 17.8%; HR, 0.94; 95% CI, 0.89–0.99; P = .028).¹ Metformin users also had a lower risk of heart failure exacerbation (5.5% vs 6.6%; HR, 0.82; 95% CI, 0.75–0.90; P < .001).¹

Haroun said clinicians should pay closer attention to patients with type 2 diabetes who are receiving VEGFi and are not taking metformin, a first-line therapy for the condition.

“It’s a low-cost medication. It’s not associated with many side effects. So it’s an opportunity to add it to our toolbox,” Haroun said.

He acknowledged the limits of the composite end point. Standardized echocardiographic surveillance would likely be more robust, but the database lacked the granularity to support it. The team kept its CTRCD definition consistent with earlier studies using the same database.

How Might Metformin Counter VEGF Inhibitor Cardiotoxicity?

Haroun pointed to in vitro and preclinical data suggesting a mechanistic rationale for metformin’s cardioprotection. Through on-target effects on the VEGF receptor, VEGF inhibitors reduce nitric oxide bioavailability in the endothelium and cause endothelial dysfunction. Metformin activates endothelial nitric oxide synthase (eNOS) and increases nitric oxide production, which Haroun described as a near-direct antagonism of this mechanism.

He noted a similar parallel outside the endothelium. VEGF inhibitors exert off-target inhibition of AMP-activated protein kinase (AMPK), a cellular energy regulator, which can disrupt energy homeostasis. Metformin, by contrast, is a known AMPK activator.

It is still unclear whether these mechanisms extend to broader cardiovascular protection. Haroun said the analysis specifically examined left ventricular systolic dysfunction, cardiomyopathy, and heart failure. His team has not studied hypertension or other VEGFi-related toxicities, which he identified as targets for future research.

What Comes Next for Metformin in Cardio-Oncology?

Haroun urged caution in interpreting the study’s oncologic signals. In the matched cohorts, metformin use was associated with lower all-cause mortality (19.8% vs 23.0%; HR, 0.83; 95% CI, 0.79–0.87; P < .001) and new-onset metastatic cancer (10.6% vs 12.8%; HR, 0.81; 95% CI, 0.74–0.88; P < .001).¹ However, he noted several prospective trials of metformin for oncologic outcomes have been disappointing.

In an updated analysis limited to patients with type 2 diabetes, the mortality and metastatic disease signals disappeared. The association between metformin and the heart failure composite remained in this population.

According to Haroun, no randomized trials have tested metformin for cardioprotection in cardio-oncology. He favors a randomized trial comparing metformin with other diabetes therapies in patients with type 2 diabetes.

“I’m a little cautious about using metformin in patients who do not have diabetes or do not have an indication for metformin,” Haroun said.

He cited the Diabetes Prevention Program, in which metformin was most helpful in preventing type 2 diabetes in younger patients, those with a BMI above 35, and those with an elevated hemoglobin A1c.² The goal, Haroun said, is to identify the patients most likely to benefit.

References:
  1. Haroun F, Dulal D, Wright J, et al. Metformin for cardioprotection during vascular endothelial growth factor inhibitor therapy: a retrospective cohort study. Abstract MDP1926. Presented at: American Heart Association Scientific Sessions 2026; November 2026; Chicago, IL.
  2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512

Advertisement
Advertisement